Tyra biosciences reports fourth quarter and full year 2024 financial results and highlights

- three inds cleared by us fda for tyra's proprietary precision small molecules - - tyra-300 to be evaluated in three phase 2 studies: surf302 for intermediate risk non-muscle invasive bladder cancer (ir nmibc), beach301 for pediatric achondroplasia (ach) and surf301 for metastatic urothelial cancer (muc) - - cash, cash equivalents, and marketable securities of $341.4 million at ye 2024; runway through at least 2027 - carlsbad, calif. , march 27, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the fourth quarter and full year ended december 31, 2024, and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking